Baseline Circulating Tumor Cell Count as a Prognostic Marker in Metastatic Castrate-Sensitive Prostate Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216)
Clin. Cancer Res 2021 Jan 26;[EPub Ahead of Print], A Goldkorn, C Tangen, M Plets, GJ Morrison, A Cunha, T Xu, JK Pinski, SA Ingles, T Triche, AL Harzstark, M Kohli, GR MacVicar, DA Vaena, AW Crispino, DJ McConkey, PN Lara, MHA Hussain, DI Quinn, NJ Vogelzang, IM Thompson, N AgarwalFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.